Niox Share Price. NIOX - Stock Quote, Charts, Trade History, Share Chat, Financials. Niox Group Plc

Gold vs US Dollar

LSE company dividends information has been updated. You can find this is in the menu on any Quote page. ADVFN team.

Home
Investing
Stocks
UK
LSE
Niox Group Plc (NIOX)
Niox Group Plc (NIOX) Share Price

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Niox Group Plc	LSE:NIOX	London	Ordinary Share	GB00BJVD3B28	ORD 0.08P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	1.00	1.64%	62.00	349,612	16:35:13

Bid Price		Offer Price	High Price	Low Price	Open Price
60.00		64.00	63.00	60.00	62.80

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceutical Preparations	33.30	16.10	3.80	-	259.70

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
16:35:13	UT	8,743	62.00	GBX

Niox (NIOX) Latest News

Niox News

Date	Time	Source	Headline
19/5/2023	10:51	UKREG	Niox Group PLC Holding(s) in Company
18/5/2023	16:26	ALNC	TRADING UPDATES: TheWorks.co.uk reports "resilient" annual performance
18/5/2023	15:47	UKREG	Niox Group PLC Result of AGM
18/5/2023	07:00	UKREG	Niox Group PLC AGM Statement
19/4/2023	18:00	UKREG	Niox Group PLC Notice of AGM
31/3/2023	10:52	UKREG	Niox Group PLC Block listing Interim Review
29/3/2023	08:03	UKREG	Niox Group PLC Director/PDMR Shareholding
28/3/2023	16:04	UKREG	Niox Group PLC Grant of options
27/3/2023	12:15	UKREG	Niox Group PLC Annual Report
24/3/2023	13:00	UKREG	Niox Group PLC Block Admission

Niox Investors Niox Takeover Rumours

Niox (NIOX) Discussions and Chat

Niox Forums and Chat

Date	Time	Title	Posts
30/5/2023	16:47	NIOX GROUP - expertise in asthma diagnosis and management	96

Add a New Thread

Niox (NIOX) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
15:35:13	62.00	8,743	5,420.66	UT
15:20:46	61.50	150,000	92,250.00	O
15:20:06	61.68	8,000	4,934.26	O
15:18:41	60.84	4	2.43	O
15:14:43	62.00	25,000	15,500.00	O

View all Niox trades in real-time

Niox (NIOX) Top Chat Posts

Top Posts
Posted at 23/5/2023 20:43 by thedudie From 4 years ago .... Oxford, UK - 19 December 2019: Circassia ...announces that it has granted nil-cost options ("Options") today over 4,322,767 ordinary shares in the Company ("Ordinary Shares") to Ian Johnson, who was appointed as Executive Chairman of the Company on 5 December 2019, under the 2019 Performance Share Plan. The Options have been granted at nil-cost and will vest on the third anniversary of the date of grant and are exercisable until the tenth anniversary of the date of grant. Vesting is subject to either the share price reaching 62.4p Nearly there I would say .... He will be happy if it passes this hurdle! Read Full Thread Follow Reply
Posted at 18/5/2023 10:23 by earwacks Typical market reaction to news. We have seen a rapid rise in the share price in recent weeks. Stockopedia has Niox a PE of 34. Not sure if that is still the case Stockopedia are tirelessly slow to update. So a bit of profit taking is inevitable. Cant deny I havnt thought about it myself, but just seems a bit too risky to duck out at this stage.the volume of buys in recent weeks has been quite relentless and some hefty stakes too. Chris Mills Harwood trust said the 65p directors bonus would not happen under its own steam.Its only a few pence short now Chris! They get another tranche of bonus if it gets into the 70s. Its certainly not cheap, but on the other hand not that expensive for the sector. I dont who you could compare it to. Quite a stash of cash and more to come. More than enough for a decent divi or even a special.do they need that much to launch the home kit I wonder? At this stage I would prefer a predator to take away the decision about top slicing please! Gl all Read Full Thread Follow Reply
Posted at 18/5/2023 07:08 by bc4 NIOX GROUP PLC AGM Statement Oxford, UK - 18 May 2023: NIOX Group plc (AIM: NIOX), a medical device company focused on point of care asthma diagnosis and management, is holding its Annual General Meeting today at the Hayakawa Building, Edmund Halley Road, Oxford Science Park. Oxford OX4 4GB. Trading Update We are pleased to report that our business has continued to perform well, with total revenues in the first 4 months of the year up 21% compared with the same period in 2022. Our core Clinical business grew strongly with revenues up 28% compared with the same period in 2022. EMEA has continued to experience strong growth, and our Asia markets have also improved significantly. In the USA, our relatively new distributor partners are starting to make an increasing contribution to revenues in the region, which were up 16% year to date compared with 2022.Ian Johnson, NIOX's Executive Chairman, said: "I am pleased to report a continuing strong trading performance in the year to date, reflecting the successful execution of our strategy. The effect of the growth in revenues, robust margins and the lower level of overheads means that adjusted EBITDA for the full year is now likely to be significantly higher than management expectations at the start of the year. The Board believes that the cash generation and resources of the Group are now at a level where it is appropriate to commence the payment of a dividend. Further details of the timing and quantum of an initial dividend payment will be announced in due course. It does not get any better than that great update Read Full Thread Follow Reply
Posted at 16/5/2023 15:07 by bc4 Taken from NIOX website FeNO by NIOX® Introducing a simple and easy way to transform your asthma care.By accurately assessing airway inflammation, FeNO testing can help improve asthma patient outcomes in one simple test, right at the point-of-care. Trusted around the world With over 45 million FeNO tests completed worldwide, NIOX® is trusted by thousands of healthcare professionals every day. Find out how FeNO by NIOX® can help make your asthma care easier. Read Full Thread Follow Reply
Posted at 11/5/2023 09:03 by earwacks Last year as Circassia we got a 4 month update at the AGM on May 12th, ahead of expectations naturally. The share price was around 35p then dipped below 30p for a couple of weeks and then continued trading between 34 to 40p range. Since then we have seen the name change and capital reduction so my feeling is 50p is not overly expensive for the updates and expectations this year especially in light of China's market opening up and of course the possibility of the launch of a home kit at some stage. This year Niox AGM is scheduled for May 18th, which hopefully will include news on first 4 months trading this year GL all Read Full Thread Follow Reply
Posted at 04/5/2023 11:57 by apad OK found it "Once FeNO testing and NIOX® are established as normal practice in Primary Care the Company plans to explore a home use product, so that asthma patients can perform a FeNO test at home and help improve their asthma outcomes." apad Read Full Thread Follow Reply
Posted at 21/3/2023 07:11 by masurenguy PRELIMINARY RESULTS FOR THE YEARED 31 DECEMBER 2022 21 March 2023: NIOX Group today announces unaudited results for the year ended 31 December 2022. Financial highlights -- Underlying revenue growth of 15% to £31.3 million (2021: £27.9 million) excluding a one-off revenue item of £0.6 million in China -- Profit before tax £2.4 million, excluding the benefit of the Beyond Air consideration of £8.1 million (2021: loss of £2.1 million) -- Group adjusted EBITDA(2) at £7.3 million, ahead of upgraded consensus estimates (2021: £0.6 million in a transitional year) -- Net cash £19.4 million (31 December 2021: £12.6 million) 2022 was a good year for the Group. The results demonstrate the clear ability of our business model to generate profitable growth, and double digit sales growth at historical trend levels was achieved despite ongoing adverse effects of Covid-19 in several of our major markets. The business has made a positive start to 2023 and the Board expects another year of solid progress, notwithstanding the somewhat mixed macroeconomic outlook. Ian Johnson, NIOX's Executive Chairman, said: "2022 was a significant year for the Group with the business substantially right-sized and the implementation of a distributor-led sales strategy well underway. These initiatives gave rise to a much-reduced cost base and generated scalable revenue growth. The Group remains debt free and has significant cash resources to continue implementing its business strategy of accessing and promoting the benefits of its products to healthcare professionals in primary and secondary care, who diagnose and treat the large population of patients suffering from asthma. Significant progress was made in 2022 to sell NIOX(R) FeNO devices into primary care, and I am pleased to report that this is continuing into 2023. The business has proved very resilient during both the Pandemic and the more recent global macroeconomic conditions. The high level of recurring revenues provides good visibility of earnings and together with high gross margins are delivering profitable growth. The Group has made a positive start to 2023 with revenues up 19% in the first two months of the year on the equivalent period in 2022. The Board believes that the strong business model will drive further top line growth and continue to deliver improved shareholder value going forward." Read Full Thread Follow Reply
Posted at 08/3/2023 10:34 by earwacks Hold? Yesterday over 7.6 million sold and share price goes up. Today a 100 bot trade takes the share price down to 48p! Crazy. Trend is undeniable though:) Read Full Thread Follow Reply
Posted at 28/2/2023 17:07 by earwacks More like a big bang after bell trades being published.chris Mills of Harwood Cap made some interesting observations. One about £600 million tax loss carry from Circassia. Two he didn't think the share price would hit the 65p bonus target set for directors under its own steam, alluding to a possible buy out. Currently just burst through the £200 million market cap. 65p would still make it about £275 million. Cheap as Read Full Thread Follow Reply
Posted at 17/1/2023 07:43 by masurenguy An ecellent Y/E trading update! Full Year Trading Update Strong business model delivering profitable growth Highlights (unaudited data) -- Underlying revenue growth of c.15% to GBP31.3m (2021: GBP27.9m) -- Adjusted EBITDA ahead of consensus expectations at approximately GBP7.0m (2021: GBP0.6m in a transitional year) -- Net cash GBP19.4m (31 December 2021: GBP12.6m) -- Good progress in expanding distribution in the USA and initial sales of NIOX into the UK primary care sector Unaudited revenues for the year ended 31 December 2022 were up 12% at approximately GBP31.3m (2021: GBP27.9m) with underlying revenues growing by 15% (excluding a one-off revenue item in 2021 of GBP0.6m). The second half of the year saw stronger relative growth of 19% over H2 2021. Gross margins improved to 71% from 68% in 2021, with recurring test kit revenues for the Clinical business continuing to represent a high proportion of Clinical sales at 89%. Group adjusted EBITDA(1) was approximately GBP7.0m (2021: GBP0.6m), ahead of market expectations which had been revised upwards twice during the year. The unaudited cash balance at the period end was GBP19.4m (31 December 2021: GBP12.6m), reflecting positive cash generation in the business and including the benefit of $2.5m received in the second half as the first milestone payment under the settlement reached with Beyond Air. The transition to a distributor-led sales strategy in our Clinical business continued throughout 2022 with the focus on building partnered distribution in USA and China. This was the principal contributor to a further substantial reduction in operating costs, with total costs of GBP15.2m down from GBP18.4m in 2021. Ian Johnson, NIOX's Executive Chairman, said: "As the impact of the global pandemic receded during 2022, sales of NIOX devices and tests continued to improve, with the increase in revenues reflecting a combination of returning customers and new sales. In our Clinical business, sales in EMEA finished well ahead of 2021 and exceeded pre pandemic levels, whilst APAC and the USA also finished ahead of 2021 but with further recovery available as they are yet to return fully to 2019 levels. Sales to our Research customers were significantly higher than in 2019. It is particularly encouraging that the NHS in the UK continues to support the use of FeNO testing, which has resulted in a significant number of additional NIOX devices being introduced into primary care, where the majority of asthma is diagnosed. The Board believes that the Company's robust business model will remain resilient to existing macroeconomic conditions and, together with the measures taken to drive top-line growth, will continue to deliver improved shareholder value going forward." NIOX expects to release Preliminary Results for the year ended 31 December 2022 on 21 March 2023. Read Full Thread Follow Reply

Niox share price data is direct from the London Stock Exchange

Your Recent History

LSE

NIOX

Niox

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea

V: D: 20230602 23:04:25